Telmisartan for the treatment of hypertension in dogs
OwnerAnne Michelle Traas, Amanda Erickson Coleman +3inventors
InventorsAnne Michelle Traas, Amanda Erickson Coleman, Bianca Natália Ferreira De Moura Lourenco, Kate Elizabeth Creevy, Scott Alan Brown
Life of this patent
Estimating the term…
Abstract
The present invention relates to telmisartan or a pharmaceutically acceptable salt thereof as a medicament for the treatment of hypertension in dogs, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period.
Claims15
A method for the treatment of hypertension in a dog in need of such treatment, wherein the dog has a systolic blood pressure (SBP) greater than 140 mmHg and the method comprises administration of a therapeutically effective amount of telmisartan or a pharmaceutically acceptable salt thereof to the dog, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of telmisartan for a first period of time during the treatment period is at least 1.0 mg/kg of body weight, and the daily dosage amount of telmisartan is increased for a second period of time subsequent the first period of time during the treatment period and in which an identified urinary protein-to-creatinine concentration (UPC) ratio is at least 0.5.
A method for the treatment of hypertension in a dog in need of such treatment, wherein the dog has a systolic blood pressure (SBP) greater than 140 mmHg and the method comprises administration of a therapeutically effective amount of telmisartan or a pharmaceutically acceptable salt thereof to the dog, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period, a first daily dosage amount of telmisartan is administered for a first period of time during the treatment period, and a second daily dosage amount of telmisartan is administered for a second period of time subsequent the first period of time during the treatment period and based upon a change in an identified urinary protein-to-creatinine concentration (UPC) ratio determined for the dog.
Dependencies are inferred from the claim text.